TX-MARY-KAY
Mary Kay recently announced its sustainability strategy – Enriching Lives Today for a Sustainable Tomorrow – which encompasses five pillars, 15 commitments, and over a decade of action. This strategy was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay an essential part of a global coalition to ensure a better future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221222005031/en/
Mary Kay Inc. partners with local and global organizations to further their mission to enrich women’s lives and bring education opportunities to young women around the world.
As part of this overarching strategy and to continue its decades-long advocacy for women’s empowerment, education and entrepreneurship, Mary Kay is committed to providing 250,000 young women education opportunities by 2030. To further its mission of enriching women’s lives, partnerships and scholarships with local and global organizations in 2022 ensured young women around the world are provided with exceptional education opportunities to pursue their dreams.
2022 Mary Kay Inc. Partnerships/Programs included:
- Young Women in STEAM Grants – Six recipients received grants created to elevate young women in STEAM fields and encourage them to continue their passions and career pursuits. The 2022 recipients were from N. Macedonia, Germany, the Philippines, China, and Australia pursuing careers in everything from app development and architecture to physics and geothermal inventions.
- Young Women in STEAM Continuing Education Grant – As an extension of Mary Kay’s Young Women in STEAM grants and social campaign, Ivanna Hernandez, a 2021 grant recipient, was awarded a second grant to help further pursue her dream of becoming the first Latin American woman astronaut to go to Mars. She was featured in a documentary created to inspire young women to shoot for the stars – or Mars in this case!
- Society of Cosmetic Chemists Madam C. J. Walker Scholarship – Established to honor Walker, the first female, self-made millionaire who made her fortune by developing a line of cosmetics and hair care products for Black women. At the SCC 75th Annual meeting, Ms. A’Lelia Bundles, the great-great-granddaughter of Madam C.J. Walker, and Michelle Hines, Ph.D., Director of Product Formulation at Mary Kay, presented the Madam C. J. Walker Scholarships for under-represented minority students pursuing higher education in STEM disciplines related to the cosmetics and personal care industry. The award is supported by the Society of Cosmetic Chemists and partnered and funded by Mary Kay. The winning recipients included: Joy Rutherford, fifth-year PhD student and NIH Research Fellow; and Imani Elaine Porter, Hampton University, second-year undergraduate in biochemistry.
- Network for Teaching Entrepreneurship – Partnering to provide 47,000 youth globally with entrepreneurship curriculum and innovative thinking opportunities. Through support of 1) the Aspiring Entrepreneurs Program (U.S.) core program; 2) World Series of Innovation; and 3) World Series of Innovation Challenge Innovation Days, Mary Kay is helping to empower youth to reach their entrepreneurial dreams. In the 2021-2022 school year, Mary Kay sponsored the NFTE World Series of Innovation (WSI) where 21 teams of emerging social entrepreneurs won a total of $16,800 for their proposed solutions to seven challenges, each of which focused on advancing a Sustainable Development Goal. Sponsors of the seven innovation challenges included: Bank of the West, Citi Foundation, Mary Kay, Saint-Gobain North America, Ernst & Young, LLP (EY), Maxar Technologies, and PIMCO. The 2022 World Series of Innovation Challenge launched in September 2022 and Mary Kay is participating for a third year tackling SDG 14: Life Below Water.
- City of Lewisville, IncubatorEDU – In partnership with the Lewisville Independent School District (LISD), IncubatorEDU offers a robust entrepreneurship curriculum to Lewisville High School students. Community mentors and an end-of-year pitch event provide the students with real-life entrepreneurial experience and education opportunities.
- Academy of Marketing Science – For more than 25 years, Mary Kay has supported the Mary Kay Dissertation and Dissertation Proposal Awards at the annual Academy of Marketing Science (AMS) conference where doctoral student participants showcase their successfully defended dissertations and receive a monetary award and critical peer feedback to improve their chances of publishing their work in academic journals in the future.
- Ursuline Academy of Dallas – Mary Kay Ash Endowed Scholarship – Scholarship awarded annually to support girls with an education that equips them with the skills and confidence needed to do great things.
- Army Scholarship Foundation - Mary Kay Corporation Honorary Scholarship – Scholarship awarded annually to deserving sons and daughters of US Army soldiers and Army veterans, and to spouses of enlisted active-duty soldiers.
- Hispanic Scholarship Fund – Scholarship awarded annually to support and empower students and parents with the knowledge and resources to successfully complete a higher education, while providing support services and scholarships to as many exceptional students, HSF scholars and Alumni as possible.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom